Indian Journal of Pharmaceutical Chemistry and Analytical Techniques (IJPCAT)
ISSN: 3049-3765 | Vol. 02, Issue-04, July-August, 2026, pp. 28-51
https://ijpcat.com/1

Molecular Docking and Simulation Studies in Drug Discovery: Principles, Applications, and Current Limitations

Perli. Kranti Kumar[1], Shrikant S. Nilewar[2*]

[1] Department of Pharmaceutical Analysis, J. K. K. Nattraja College of Pharmacy, Kumarapalayam, Namakkal, Tamil Nadu - 638183
[2]Department of Pharmaceutical Chemistry, Maliba Pharmacy College, Uka Tarsadia University,Bardoli 394350, Gujarat, India

***Corresponding Author E-mail: shrinilewar@gmail.com**

Abstract:

Molecular docking and molecular dynamics (MD) simulations have become indispensable tools in modern drug discovery, enabling researchers to accelerate the identification and optimisation of therapeutic compounds. This comprehensive review examines the fundamental principles underlying these computational approaches, their diverse applications in pharmaceutical development, and the significant limitations that currently constrain their predictive accuracy and applicability. We discuss structure-based drug design methodologies, scoring functions, binding-affinity prediction, conformational sampling strategies, and the integration of artificial intelligence into computational drug discovery. Furthermore, we address critical challenges, including protein flexibility representation, ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction accuracy, and the persistent discrepancy between in silico predictions and experimental validation. Recent advances in hardware acceleration, force-field development, and machine learning are reshaping the landscape of computational drug discovery. This review synthesises current knowledge and highlights future opportunities for enhancing the reliability and efficiency of molecular docking and simulation studies in pharmaceutical research.

Keywords: Molecular Docking, Molecular Dynamics Simulations, Structure-Based Drug Design, Scoring Functions, Binding Affinity, ADMET Prediction, Computer-Aided Drug Design, Drug Discovery

Received: April 17, 2026 **Revised: May 21, 2026** **Accepted: 18 June, 2026** **Published: August 5, 2026**

DOI: https://doi.org/10.64062/IJPCAT.Vol2.Issue4.2

https://ijpcat.com/index.php/1/issue/archive

1. Introduction

1.1 Overview of Drug Discovery

The modern pharmaceutical development pipeline represents one of the most resource-intensive endeavours in scientific research, typically requiring 10–15 years and investments exceeding $2.6 billion to bring a single drug to market [1]. The attrition rate remains remarkably high, with approximately 90% of drug candidates failing during clinical development stages, predominantly due to insufficient efficacy, poor pharmacokinetic properties, and unexpected toxicity [2]. The fundamental challenge lies in identifying compounds that effectively modulate specific biological targets while maintaining acceptable safety and bioavailability profiles [3].

1.2 Role of Computational Methods

Computational chemistry and molecular modelling have emerged as critical strategies to expedite drug discovery timelines and reduce development costs. These approaches enable researchers to screen vast chemical libraries, predict biological activity, and optimise lead compounds before committing to expensive synthetic chemistry and biological testing campaigns [4.] Relying on three-dimensional protein structures and molecular docking methodologies, structure-based drug design has revolutionised the engagement and validation of therapeutic targets [5].

1.3 Significance of Molecular Docking and Simulation

Molecular docking and molecular dynamics simulations represent complementary computational techniques that provide atomic-level insights into ligand-protein interactions. Molecular docking predicts the optimal binding poses and orientations of small-molecule ligands within target protein binding sites, while MD simulations explore the dynamic behaviour of these complexes over time [6]. Together, these methods enable researchers to:

- Predict binding modes and affinities between drug candidates and biological targets.
- Screen large virtual libraries for promising compounds.
- Validate experimental hypotheses regarding the mechanism of action.
- Guide rational modification of lead structures to enhance potency and selectivity.
- Investigate off-target interactions and potential mechanisms of toxicity.
- Study protein conformational dynamics relevant to drug action.

This review provides a comprehensive examination of molecular docking and simulation methodologies, their practical applications in pharmaceutical discovery, and the significant limitations that must be addressed to enhance their predictive reliability.

2. Fundamental Principles of Molecular Docking

2.1 Molecular Recognition and Non-Covalent Interactions

Drug-target interactions are predominantly governed by non-covalent interactions, including hydrogen bonding, electrostatic interactions, van der Waals forces, and hydrophobic effects [7]. The fundamental principle of molecular recognition states that ligands with favourable

thermodynamic and kinetic properties within the binding pocket exhibit enhanced binding affinity and selectivity [8]. These interactions typically occur at dissociation constants ranging from nanomolar to micromolar concentrations, representing the optimal balance between binding strength and selectivity. Figure 2



Figure 2. Molecular Docking Concepts: Sampling Strategies, Scoring Functions, and Binding Interactions

2.2 The Docking Problem: Pose and Scoring

Molecular docking addresses two fundamental challenges: (1) **sampling**, the identification of likely ligand binding poses within the target binding site, and (2) **scoring**, the ranking of these poses according to their predicted binding affinity [9]. The sampling problem requires exploring the conformational spaces of the ligand and, in some cases, the target protein to identify energetically favourable orientations. The scoring challenge involves developing mathematical functions that accurately correlate computed binding scores with experimental binding affinities [10].

2.3 Docking Algorithms: Classification and Approaches

Molecular docking algorithms can be broadly categorised into several classes:

2.3.1 Rigid Receptor Docking

Traditional docking approaches assume the protein receptor maintains a rigid conformation, substantially reducing computational complexity. Algorithms such as AutoDock, AutoDock Vina, and GOLD exemplify this category, employing various conformational search methodologies to identify optimal ligand orientations within a static binding pocket [11]. While computationally efficient, rigid receptor approaches often fail to account for conformational

adjustments that accompany ligand binding, potentially missing bioactive poses or incorrectly scoring alternative binding modes.

2.3.2 Flexible Receptor Docking

More sophisticated approaches incorporate protein flexibility by either using pre-computed conformational ensembles or employing soft-potential functions that permit modest atomic displacements [12]. Methods such as Induced Fit Docking (IFD) explicitly model receptor conformational changes during ligand binding, more accurately representing biological reality. However, the need for comprehensive receptor flexibility incurs substantial computational costs, potentially rendering large-scale virtual screening impractical [13].

2.3.3 Sampling Methodologies

Grid-based methods precompute protein-ligand interaction potentials on three-dimensional grids, enabling rapid calculation of ligand-receptor interaction energies [14]. These methods benefit from exceptional computational speed but sacrifice accuracy in representing continuous interaction energies.

Stochastic sampling algorithms, including Genetic Algorithms (GA) and Simulated Annealing (SA), probabilistically explore conformational space by proposing random perturbations and accepting or rejecting these modifications based on energy criteria [15]. These methods are particularly effective for flexible ligands with multiple rotatable bonds.

Pharmacophore-based approaches utilise patterns of essential molecular features (hydrogen bond donors/acceptors, hydrophobic centres, and aromatic rings) rather than explicit atomic coordinates, enabling rapid virtual screening and identification of chemically diverse scaffolds that fulfil spatial requirements [16].

2.4 Scoring Functions: Theory and Classification

Scoring functions are mathematical models that predict binding affinity based on receptor-ligand interactions and ligand properties. These functions face the formidable challenge of balancing accuracy with computational speed, as thousands to millions of compounds may need to be evaluated [17].

2.4.1 Force Field-Based Scoring

Force field approaches apply classical mechanical energy calculations, encompassing:

- Bond stretching and angle bending energies
- Torsional strain contributions from dihedral angle distortions
- Van der Waals interactions, typically represented by Lennard-Jones potentials
- Electrostatic interactions, calculated using partial charges and Coulomb's law

Representative implementations include CHARMM, AMBER, and MMFF94 force fields. While theoretically rigorous, force-field-based scoring often overestimates binding affinity by failing to properly account for solvation effects and protein conformational entropy [18].

2.4.2 Empirical Scoring Functions

Empirical approaches statistically correlate binding affinity with molecular descriptors derived from training sets of experimentally characterised complexes. Functions such as ChemScore, Chemscore, and Autodock employ weighted sums of interaction terms:

$$\Delta G = \Delta G_{\text{vdW}} + \Delta G_{\text{hbond}} + \Delta G_{\text{metal}} + \Delta G_{\text{rot}}$$

where components represent van der Waals, hydrogen bond, metal coordination, and rotational entropy contributions [19]. These functions are computationally expedient but demonstrate limited transferability across chemically diverse datasets and protein families.

2.4.3 Knowledge-Based Scoring

Knowledge-based functions, such as DrugScore and PMF (Potential of Mean Force), derive statistical preferences for interatomic distances from databases of protein-ligand crystal structures [20]. These approaches leverage empirical observations but may overfit to structural biases present in the Protein Data Bank (PDB).

2.4.4 Machine Learning-Based Scoring

Recent advances employ neural networks, random forests, gradient boosting machines, and support vector machines to learn complex relationships between molecular features and binding affinity [21]. Machine learning approaches demonstrate superior predictive accuracy compared to traditional scoring functions but require extensive training datasets and careful validation to prevent overfitting [22]. Figure 1



Figure 1. Integrated Workflow of Molecular Docking and Molecular Dynamics in Drug Discovery

3. Molecular Dynamics Simulations: Theory and Applications

3.1 Fundamentals of Molecular Dynamics

Molecular dynamics simulations propagate atomic coordinates over time by numerically integrating Newton's equations of motion:

$$\mathbf{F}_i = m_i \frac{d^2\mathbf{r}_i}{dt^2}$$

where$\mathbf{F}_i$ represents the force on atom i, m_i denotes its mass, and$\mathbf{r}_i$ is its position vector [23]. Forces are computed from potential energy functions typically empirical force fields that model bonded interactions (bonds, angles, dihedrals) and non-bonded interactions (van der Waals, electrostatics). Integration employs finite time steps (typically 1-2 femtoseconds) to ensure numerical stability while balancing computational efficiency [24].

3.2 Force Fields and Their Components

Modern force fields partition the potential energy into distinct terms:

$$V_{\text{total}} = V_{\text{bonded}} + V_{\text{nonbonded}}$$

where:

$$V_{\text{bonded}} = \sum_{\text{bonds}} k_b(r - r_0)^2 + \sum_{\text{angles}} k_a(\theta - \theta_0)^2 + \sum_{\text{dihedrals}} V_n[1 + \cos(n\phi - \gamma)]$$

and:

$$V_{\text{nonbonded}} = \sum_{i<j} \left[4\epsilon_{ij} \left(\left(\frac{\sigma_{ij}}{r_{ij}} \right)^{12} - \left(\frac{\sigma_{ij}}{r_{ij}} \right)^{6} \right) + \frac{k_e q_i q_j}{r_{ij}} \right]$$

Popular force fields, including AMBER, CHARMM, GROMOS, and OPLS, employ similar functional forms with parameterisations optimised for specific molecular classes [25]. Recent developments address the limitations of traditional force fields, including the improved treatment of aromatic rings, non-bonded interactions, and polarisation effects [26].

3.3 Conformational Sampling and Enhanced Sampling Methods

Standard MD simulations efficiently explore relatively shallow energy landscapes but often require impractical simulation times to surmount substantial energy barriers separating conformational substates. Several enhanced sampling techniques have been developed to address this limitation:

3.3.1 Replica Exchange Molecular Dynamics (REMD)

REMD executes multiple MD simulations in parallel at different temperatures, periodically exchanging configurations between replicas according to Metropolis-Hastening's criteria [27]. This approach effectively traverses energy barriers by performing searches at elevated temperatures while preserving the canonical ensemble at physiological temperatures. REMD exhibits utility for systems with complex energy landscapes and multiple local minima [28].

3.3.2 Metadynamics

Metadynamics augments the potential energy with history-dependent bias functions deposited at configurations visited during the simulation, progressively flattening the free energy landscape [29]. This method enables exploration of previously inaccessible regions while still recovering meaningful free energy information. Metadynamics proves particularly valuable for studying rare events and conformational transitions relevant to drug binding [30].

3.3.3 Umbrella Sampling and Steered MD

Umbrella sampling applies biasing potentials along defined reaction coordinates to force exploration of higher-energy regions [31]. Steered MD applies external forces to guide the system along predefined pathways, helpful in studying protein-ligand unbinding events and forced dissociation mechanisms [32].

3.4 Binding Affinity Prediction from Simulations

Accurate binding affinity prediction represents a central objective of structure-based drug design. Several simulation-based methodologies have been developed:

3.4.1 MM/GB (PB) SA Approaches

The Molecular Mechanics/Generalised Born (or Poisson-Boltzmann) Surface Area method combines molecular mechanical energies with implicit solvation models to estimate binding free energies [33].

$$\Delta G_{\text{bind}} = \Delta G_{\text{MM}} + \Delta G_{\text{solv}} + \Delta G_{\text{entropy}}$$

where ΔG_{MM} represents gas-phase molecular mechanics energy changes, ΔG_{solv} encompasses solvation free energy contributions, and $\Delta G_{\text{entropy}}$ accounts for conformational entropy changes upon binding [34]. While computationally efficient and routinely applicable to large systems, MM/GB(PB)SA approaches often exhibit substantial errors (1-2 kcal/mol) relative to experimental values due to imprecise entropy estimates and simplified solvation models [35].

3.4.2 Alchemical Free Energy Calculations

Alchemical methods employ thermodynamic integration or free energy perturbation (FEP) to compute binding free energies by establishing thermodynamic pathways connecting bound and unbound ligand states [36]. These approaches theoretically provide superior accuracy compared to MM/GB (PB) SA, but they demand substantially more computational resources, often limiting their applicability to specialised computing facilities [37].

3.4.3 Kinetic Methods

Binding kinetics, particularly association (k_{on}) and dissociation (k_{off}) rate constants can be estimated from MD simulations through approaches including molecular dynamics in vacuo followed by implicit solvation calculations or by extrapolating kinetic information from steered MD trajectories [38]. These kinetic parameters often prove more biologically relevant than equilibrium binding affinities for understanding drug efficacy and duration of action [39].

4. Applications of Molecular Docking and Simulations

4.1 Virtual Screening and Lead Discovery

Virtual screening represents one of the most widespread applications of molecular docking, enabling the rapid evaluation of large chemical libraries to identify compounds with favourable predicted bindings to therapeutic targets [40]. Structure-based virtual screening leverages three-dimensional crystal structures or homology models to computationally dock millions of compounds, ranking them by predicted binding affinity [41].

Case Study: KLHDC2 Ubiquitin Ligase Discovery

Recent advances in AI-accelerated virtual screening have demonstrated remarkable success in ultra-large library screening. A study employing the RosettaVS platform screened billions of compounds against the KLHDC2 ubiquitin ligase, a previously undrugged target lacking known small-molecule binders [42.] The computational pipeline identified promising compounds that were subsequently experimentally validated through binding assays and X-ray crystallography. Notable success metrics included identification of multiple compounds with nanomolar binding affinities and strong structural agreement between predicted and crystallographically determined binding poses [43].

4.2 Lead Optimization and Structure-Activity Relationship (SAR) Studies

Molecular docking and simulations guide iterative lead optimization by predicting how structural modifications influence binding affinity and selectivity. Medicinal chemists employ docking results to rationalise experimental observations, design targeted modifications, and prioritise synthetic efforts [44]. MD simulations reveal dynamic binding modes and conformational preferences that inform structure modifications yielding enhanced potency and selectivity [45.]

4.3 Target Validation and Druggability Assessment

Computational approaches predict whether protein targets possess characteristics enabling effective small-molecule modulation. Druggability assessments evaluate binding pocket volume, hydrophobicity, amino acid composition, and accessibility from the protein surface [46]. MD simulations identify cryptic binding pockets that emerge transiently during protein dynamics, potentially expanding druggable surface areas [47.] These analyses guide resource allocation within discovery programs by identifying targets that are more amenable to chemical intervention [48].

4.4 Selectivity and Off-Target Prediction

Predicting selection across target families is critical for minimising adverse effects. Cross-docking studies evaluate predicted binding to off-target proteins, identifying potential safety liabilities [49]. MD simulations of ligand-protein complexes elucidate molecular mechanisms responsible for selectivity differences, informing design strategies to enhance target selectivity while reducing off-target engagement [50].

4.5 Protein Conformational Analysis and Allosteric Mechanisms

MD simulations uniquely characterise protein dynamics, conformational transitions, and allosteric communication pathways relevant to drug action [51]. Simulations of intrinsically

disordered proteins (IDPs), historically resistant to structural and computational characterisation, now enable a mechanistic understanding of their functional dynamics [52]. Extended simulations tracking protein conformational changes upon drug binding illuminate allosteric mechanisms through which ligands modulate biological function [53].

4.6 ADMET Prediction and Pharmacokinetic Profiling

While traditional ADMET prediction relied upon quantitative structure-activity relationship (QSAR) models or empirical rules, structure-based approaches now incorporate the three-dimensional protein structures of metabolising enzymes (CYP450 family members, UDP-glucuronosyltransferases), transporters (P-glycoproteins), and other ADMET-related proteins [54]. Molecular docking to these proteins predicts substrate specificity, metabolic stability, and potential drug-drug interactions [55]. Recent machine learning approaches integrate structural information with multi-omics data to enhance ADMET predictions [56].

4.7 Nanoparticle Drug Delivery Systems

Molecular dynamics simulations have expanded to encompass pharmaceutical nanotechnology, enabling atomic-level investigation of drug-nanocarrier interactions, nanoparticle biodistribution, cellular uptake mechanisms, and cargo release kinetics [57]. Simulations of lipid bilayers, polymeric matrices, and protein corona formation around nanoparticles guide rational design of advanced drug delivery systems [58]. These applications represent a growing frontier in computational pharmaceutical development [59].

4.8 Structure-Based Discovery Against Pandemic Threats

During the COVID-19 pandemic, molecular docking and simulations played pivotal roles in rapidly identifying promising therapeutic candidates targeting SARS-CoV-2 proteins [60]. Virtual screening campaigns screened millions of compounds against viral proteases (3CLpro, PLpro) and spike proteins, identifying compounds subsequently validated experimentally [61]. This experience demonstrated the critical role of computational approaches in enabling rapid responses to emerging health threats.

5. Integration of Artificial Intelligence and Machine Learning

5.1 Machine Learning for Scoring and Affinity Prediction

Traditional scoring functions often demonstrate limited transferability and accuracy, particularly for diverse chemical scaffolds. Machine learning approaches learn complex non-linear relationships between molecular features and binding affinity from large training datasets [62]. Neural networks, random forests, gradient boosting machines, and other algorithms have demonstrated superior predictive performance compared to conventional scoring functions [63].

Recent deep learning architectures employ graph neural networks (GNNs), which represent molecular structures as graphs where atoms are nodes and bonds are edges, enabling the learning of task-specific molecular representations without explicit feature engineering [64]. These representations capture inherent molecular patterns relevant to binding interactions, substantially improving prediction accuracy [65].

5.2 AI-Accelerated Virtual Screening

Active learning strategies dramatically accelerate virtual screening by iteratively improving machine learning models during docking computations [66]. Rather than exhaustively docking all compounds, active learning approaches identify the most promising compounds for expensive physics-based docking, enabling billion-compound screening campaigns to complete in practical timeframes [67]. The RosettaVS platform exemplifies this approach, employing neural networks to triage compounds while maintaining high sensitivity for identifying true binders [68].

5.3 Generative Models for De Novo Drug Design

Generative adversarial networks (GANs), variational autoencoders (VAEs), and other generative models learn the chemical spaces of known bioactive compounds, enabling the computational generation of novel structures with predicted favourable properties [69]. These approaches bypass virtual screening constraints by directly generating candidate molecules, potentially discovering scaffolds inaccessible through optimization of existing leads [70].

5.4 Multi-Task Learning for Integrated ADMET Prediction

ADMET properties exhibit inherent interdependencies rather than independence; absorption influences distribution, metabolism generates active metabolites, and excretion kinetics depend on metabolic transformations [71]. Multi-task learning architectures predict multiple ADMET endpoints simultaneously, leveraging shared representations to improve individual predictions [72]. These integrated approaches better capture the complex relationships governing pharmacokinetic behaviours [73].

6. Current Limitations and Challenges

6.1 Protein Flexibility and Conformational Dynamics

A fundamental limitation of molecular docking involves accurate representation of protein flexibility. Static receptor structures incompletely represent the conformational ensemble that proteins sample in solution [74]. While flexible docking approaches exist, comprehensive treatment of receptor flexibility introduces prohibitive computational costs, particularly for large-scale virtual screening [75]. Furthermore, explicitly accounting for water molecules and ions within binding pockets remains computationally challenging [76].

6.2 Sampling and Convergence Issues

MD simulations face inherent limitations regarding conformational sampling and timescale accessibility. Many biologically relevant processes, including protein folding, allosteric transitions, and association/dissociation events, occur on microsecond-to-second timescales, far exceeding practical simulation durations [77]. Enhanced sampling methods partially address this limitation but introduce complications regarding interpretation of results and free energy recovery [78].

6.3 Force Field Limitations

Current force fields rely on approximations and parameterizations primarily developed from small-molecule databases and simple protein systems [79]. These force fields inadequately represent certain molecular classes, including metal-organic species, non-standard amino acids, and post-translationally modified residues [80]. Polarisation effects are often approximated through fixed partial charges, incompletely capturing electronic responses to chemical environment changes [81].

6.4 Scoring Function Accuracy and Transferability

Despite technological advances, scoring functions typically exhibit root mean square errors of 1-2 kcal/mol when predicting binding affinities, comparable to thermal energy at physiological temperature [82]. This modest accuracy substantially limits the ability to accurately rank compounds or predict minor affinity improvements from structural modifications [83]. Moreover, scoring functions typically demonstrate poor transferability across chemically diverse compound classes and target protein families [84].

6.5 ADMET Prediction Accuracy and Applicability Domain

ADMET predictions remain subject to substantial uncertainties. QSAR models demonstrate limited applicability domains, requiring chemical similarity to training set compounds to maintain prediction reliability [85]. Structure-based ADMET approaches employing docking to metabolise enzymes and transporters remain limited by enzyme promiscuity; these proteins exhibit broad substrate specificity that computational models inadequately capture [86]. Additionally, predictions focusing on single properties often fail to account for property interdependencies governing overall pharmacokinetic behaviour [87].

6.6 Solvent and Desolvation Effects

Accurate treatment of solvation effects remains a critical unresolved challenge. Most scoring functions inadequately account for desolvation costs required when displacing water molecules from binding sites [88]. Implicit solvation models employed in MM/GB(PB)SA calculations approximate continuous solvent environments but fail to represent significant discrete solvation effects and water-mediated hydrogen bonding networks [89]. Explicit water simulations substantially increase computational demands [90].

6.7 Entropy Contributions and Conformational Entropy

Accurate accounting for entropy changes accompanying binding represents a persistent limitation. Most approaches either ignore conformational entropy or employ crude approximations such as counting rotatable bonds or calculating vibrational entropy from short MD trajectories [91]. Translational and rotational entropy of the ligand upon binding is incompletely represented by current methods [92]. These entropy limitations often result in binding affinity overpredictions ranging from 2–3 kcal/mol [93].

6.8 Validation and Experimental Discrepancies

A critical limitation involves a disconnect between computational predictions and experimental observations. Docking poses frequently do not correlate with experimentally determined

crystal structures, with root mean square deviations exceeding 2-3 Ångströms [94]. Predicted binding affinities often correlate poorly with experimental values, with correlation coefficients frequently below 0.6–0.7 [95]. These discrepancies suggest fundamental inadequacies in our computational treatment of protein-ligand interactions or potentially experimental artefacts [96].

6.9 Lack of Standardisation and Reproducibility

Molecular docking and simulation protocols lack standardisation, with researchers employing diverse parameter sets, force fields, and methodological choices [97]. This heterogeneity complicates meta-analyses, method comparisons, and integration of results across studies [98]. Reproducibility challenges extend from inherent stochasticity in simulation approaches to differences in software implementations [99].

6.10 Computational Resource Requirements and Accessibility

Although computational power has increased dramatically, truly realistic simulations encompassing explicit solvent, membrane environments, and biologically relevant timescales demand extensive computational resources that remain inaccessible to many academic research groups [100]. This creates inequitable access to advanced computational methods and potentially biases discovery toward pharmaceutical companies and well-funded research institutions [101]. Figure 3



Figure 3. Current Limitations and Emerging Solutions in Docking and MD Simulations

7. Recent Advances and Future Perspectives

7.1 Hardware Acceleration and Specialised Computing

Application-specific integrated circuits (ASICs) and custom-designed chips explicitly optimised for molecular dynamic acceleration have dramatically enhanced simulation

capabilities. The Anton series of supercomputers, specifically architected for MD simulation, enabled millisecond-duration all-atom simulations of small proteins that previously required computational infeasibility [102]. Similar specialised hardware development continues, with field-programmable gate arrays (FPGAs) and graphics processing units (GPUs) increasingly being deployed for molecular docking and simulation acceleration [103].

7.2 Hybrid Quantum-Classical Methods

Quantum mechanical/molecular mechanical (QM/MM) hybrid approaches enable more accurate treatment of active site chemistry while maintaining computational tractability [104]. Recent developments in density functional theory (DFT) acceleration and machine learning-based potential energy surfaces promise to enhance the accuracy of catalytic mechanism simulations and binding interaction calculations [105].

7.3 Deep Learning and Structure Prediction

Deep learning approaches have revolutionised protein structure prediction, as exemplified by AlphaFold2, which achieved near-experimental accuracy without explicit evolutionary information [106]. These predictions expand the applicability of structure-based computational methods to previously unsolved protein structures, substantially broadening virtual screening and docking applications [107]. AlphaFold2 predictions of protein-protein interactions and conformational ensembles further enhance capacity for dynamic drug target characterization [108].

7.4 Interpretable Machine Learning and Explainable AI

As machine learning increasingly dominates computational drug discovery, emphasis on interpretability and explainability has grown. Techniques such as SHAP values, LIME, and attention mechanisms elucidate which molecular features drive predictions, enhancing the trustworthiness and actionability of computational results [109]. This interpretability is particularly critical for the regulatory acceptance and clinical translation of computationally assisted drug development programs [110].

7.5 Integration of Multi-Scale Modeling

Combining quantum mechanical calculations of specific interactions with classical MD simulations of larger protein systems and incorporating continuum-level descriptions of cellular phenomena enables unprecedented capacity to bridge length and timescales [111]. These multi-scale approaches promise a more comprehensive understanding of drug action within cellular contexts [112].

7.6 Cryo-EM Integration and Conformational Ensembles

Cryo-electron microscopy has provided unprecedented insights into protein conformational heterogeneity and dynamics. Integration of cryo-EM-derived ensemble representations with molecular dynamics simulations enables more biologically realistic sampling of conformational space than crystal structures alone [113]. This convergence of structural biology and computational methods promises enhanced accuracy of docking and simulation predictions [114].

8. Regulatory and Practical Considerations

8.1 Regulatory Acceptance of Computational Methods

Regulatory agencies, including the FDA and EMA, increasingly recognise computational methods in drug development decision-making [115]. However, standardised and validated computational approaches remain critical for broader regulatory acceptance [116]. Transparent reporting of computational methodologies, validation against experimental data, and demonstration of reproducibility strengthen regulatory submissions incorporating computational evidence [117].

8.2 Best Practices and Standardisation Efforts

Organisations, including the Computational Medicinal Chemistry Working Group and the European Cooperation in Science and Technology (COST) Initiative, have developed guidelines and best practices for molecular docking and simulation applications [118]. Consensus protocols regarding protein preparation, ligand parameterisation, and result validation improve the reliability of methods and the comparability of studies [119].

8.3 Cost-Benefit Analysis and Integration into Discovery Pipelines

While computational methods demand significant upfront infrastructure and expertise investments, their cost-benefit calculus strongly favours their integration into drug discovery pipelines [120]. Virtual screening and computational lead optimisation substantially reduce the requirements for synthetic chemistry and biological testing, offsetting computational resource investments by multiple fold [121-122].

9. Conclusion

Molecular docking and molecular dynamics simulations have fundamentally transformed pharmaceutical drug discovery, enabling rapid screening of vast chemical libraries, rational lead optimisation and mechanistic characterisation of drug-target interactions. Ongoing technological advances, including enhanced sampling methods, specialised computing hardware, machine learning integration, and hybrid quantum-classical approaches, continue to expand the applicability and accuracy of computational methods.

However, substantial limitations persist. Modest scoring function accuracy, inadequate representation of protein flexibility, incomplete entropy treatment, and persistent discrepancies between computational predictions and experimental observations constrain current capabilities. These challenges motivate continued methodological development, field refinement, and validation studies that bridge computational predictions and experimental outcomes.

The integration of artificial intelligence and machine learning has accelerated virtual screening and improved binding affinity predictions, though at the potential cost of mechanistic interpretability. Future progress requires a balanced emphasis on both enhanced predictive accuracy and preservation of chemical and biological interpretability.

As computational power continues to increase, force fields improve, and machine learning methods mature, molecular docking and simulation studies promise to become even more central to drug discovery. The convergence of computational methods with emerging technologies, including cryo-EM, AlphaFold predictions, and multi-scale modelling, offers unprecedented opportunities to enhance our understanding of protein function and to enable rational therapeutic interventions.

Successful integration of these computational approaches into pharmaceutical development requires ongoing collaboration between computational chemists, structural biologists, biochemists, and medicinal chemists. Such interdisciplinary partnerships, coupled with a commitment to method validation and standardisation, position computational chemistry to fulfil its promise of accelerating the development of safe, efficacious therapeutics that address unmet medical needs.

References

1. Prieto-Martínez, F. D., López-López, E., Eurídice Juárez-Mercado, K., & Medina-Franco, J. L. (2019). Computational drug design methods: Current and future perspectives. *In Silico Drug Design*, *3*(3), 19–44. https://doi.org/10.1016/B978-0-12-816125-8.00002-X
2. Kapetanovic, I. M. (2008). Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. *Chemico-Biological Interactions*, *171*(2), 165–176. https://doi.org/10.1016/j.cbi.2006.12.006
3. Barril, X. (2017). Computer-aided drug design: Time to play with novel chemical matter. *Expert Opinion on Drug Discovery*, *12*(10), 977–980. https://doi.org/10.1080/17460441.2017.1362386
4. Deore, A. B., Dhumane, J. R., Wagh, R., & Sonawane, R. (2019). The stages of drug discovery and development process. *Asian Journal of Pharmaceutical Research and Development*, *7*(6), 62–67. https://doi.org/10.22270/ajprd.v7i6.616
5. Muhammed, M. T., & Aki-Yalcin, E. (2021). Pharmacophore modeling in drug discovery: Methodology and current status. *Journal of the Turkish Chemical Society Section A: Chemistry*, *8*(3), 759–772.
6. Surabhi, S., & Singh, B. K. (2018). Computer aided drug design: An overview. *Journal of Drug Delivery and Therapeutics*, *8*(5), 504–509. https://doi.org/10.22270/jddt.v8i5.1894
7. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W., Jr. (2014). Computational methods in drug discovery. *Pharmacological Reviews*, *66*(1), 334–395. https://doi.org/10.1124/pr.112.007336
8. Ou-Yang, S., Lu, J., Kong, X., Liang, Z., Luo, C., & Jiang, H. (2012). Computational drug discovery. *Acta Pharmacologica Sinica*, *33*(9), 1131–1140. https://doi.org/10.1038/aps.2012.109
9. Bisht, N., & Singh, B. K. (2018). Role of computer aided drug design in drug development and drug discovery. *International Journal of Pharmaceutical Sciences and Research*, *9*(4), 1405–1415. https://doi.org/10.13040/IJPSR.0975-8232.9(4).1405-15

10. Salmaso, V., & Moro, S. (2018). Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. *Frontiers in Pharmacology*, *9*, Article 923. https://doi.org/10.3389/fphar.2018.00923
11. Ferreira, L., dos Santos, R., Oliva, G., & Andricopulo, A. (2015). Molecular docking and structure-based drug design strategies. *Molecules*, *20*(7), 13384–13421. https://doi.org/10.3390/molecules200713384
12. Jones, L. H., & Bunnage, M. E. (2017). Applications of chemogenomic library screening in drug discovery. *Nature Reviews Drug Discovery*, *16*(4), 285–296. https://doi.org/10.1038/nrd.2016.244
13. Chahal, V., Nirwan, S., & Kakkar, R. (2019). Combined approach of homology modeling, molecular dynamics, and docking: Computer-aided drug discovery. *Physical Sciences Reviews*, *4*(10), 1–15. https://doi.org/10.1515/psr-2019-0066
14. Macalino, S. J. Y., Billones, J. B., Organo, V. G., & Carrillo, M. C. O. (2020). In silico strategies in tuberculosis drug discovery. *Molecules*, *25*(3), Article 665. https://doi.org/10.3390/molecules25030665
15. Hecht, D., & Fogel, G. B. (2009). Computational intelligence methods for docking scores. *Current Computer-Aided Drug Design*, *5*(1), 56–68. https://doi.org/10.2174/157340909787580863
16. Meyers, J., Fabian, B., & Brown, N. (2021). De novo molecular design and generative models. *Drug Discovery Today*, *26*(11), 2707–2715. https://doi.org/10.1016/j.drudis.2021.05.019
17. Mouchlis, V. D., Afantitis, A., Serra, A., Fratello, M., Papadiamantis, A. G., Aidinis, V., Lynch, I., Greco, D., & Melagraki, G. (2021). Advances in de novo drug design: From conventional to machine learning methods. *International Journal of Molecular Sciences*, *22*(4), Article 1676. https://doi.org/10.3390/ijms22041676
18. Sulimov, A., Kutov, D., Ilin, I., Zheltkov, D., Tyrtyshnikov, E., & Sulimov, V. (2019). Supercomputer docking with a large number of degrees of freedom. *SAR and QSAR in Environmental Research*, *30*(10), 733–749. https://doi.org/10.1080/1062936X.2019.1659412
19. Muhammed, M. T., Kuyucuklu, G., Kaynak-Onurdag, F., & Aki-Yalcin, E. (2022). Synthesis, antimicrobial activity, and molecular modeling studies of some benzoxazole derivatives. *Letters in Drug Design & Discovery*, *19*(8), 757–768. https://doi.org/10.2174/1570180819666220408133643
20. Chen, Y. C. (2015). Beware of docking! *Trends in Pharmacological Sciences*, *36*(2), 78–95. https://doi.org/10.1016/j.tips.2014.12.001
21. Tuccinardi, T., Poli, G., Romboli, V., Giordano, A., & Martinelli, A. (2014). Extensive consensus docking evaluation for ligand pose prediction and virtual screening studies. *Journal of Chemical Information and Modeling*, *54*(10), 2980–2986. https://doi.org/10.1021/ci500424n[12]
22. Dar, A. M., & Mir, S. (2017). Molecular docking: Approaches, types, applications and basic challenges. *Journal of Analytical & Bioanalytical Techniques*, *8*(2), 1–3. https://doi.org/10.4172/2155-9872.1000356
23. Elokely, K. M., & Doerksen, R. J. (2013). Docking challenge: Protein sampling and molecular docking performance. *Journal of Chemical Information and Modeling*, *53*(8), 1934–1945. https://doi.org/10.1021/ci400040d

24. Pinzi, L., & Rastelli, G. (2019). Molecular docking: Shifting paradigms in drug discovery. *International Journal of Molecular Sciences*, *20*(18), Article 4331. https://doi.org/10.3390/ijms20184331
25. Phillips, M. A., Stewart, M. A., Woodling, D. L., & Xie, Z. (2018). Has molecular docking ever brought... *US Medicine*, *1*, 141–179. https://doi.org/10.5772/57353
26. Ludovici, D. W., De Corte, B. L., Kukla, M. J., Ye, H., Ho, C. Y., Lichtenstein, M. A., Kavash, R. W., Andries, K., de Béthune, M. P., Azijn, H., Pauwels, R., Lewi, P. J., Heeres, J., Koymans, L. M. H., de Jonge, M. R., Van Aken, K. J. A., Daeyaert, F. F. D., Das, K., Arnold, E., & Janssen, P. A. J. (2001). Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. *Bioorganic & Medicinal Chemistry Letters*, *11*(17), 2235–2239. https://doi.org/10.1016/S0960-894X(01)00412-7
27. Janssen, P. A. J., Lewi, P. J., Arnold, E., Daeyaert, F., de Jonge, M., Heeres, J., Koymans, L., Vinkers, M., Guillemont, J., Pasquier, E., Kukla, M., Ludovici, D., Andries, K., de Béthune, M. P., Pauwels, R., Das, K., Clark, A. D., Jr., Frenkel, Y. V., Hughes, S. H., ... Williams, P. (2005). In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of R278474 (rilpivirine). *Journal of Medicinal Chemistry*, *48*(6), 1901–1909. https://doi.org/10.1021/jm040840e
28. Zhang, P., Bao, L., Fan, J., Jia, Z. J., Sinha, U., Wong, P. W., Park, G., Hutchaleelaha, A., Scarborough, R. M., & Zhu, B. Y. (2009). Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR. *Bioorganic & Medicinal Chemistry Letters*, *19*(8), 2186–2189. https://doi.org/10.1016/j.bmcl.2009.02.114
29. Zhang, P., Huang, W., Wang, L., Bao, L., Jia, Z. J., Bauer, S. M., Goldman, E. A., Probst, G. D., Song, Y., Su, T., Fan, J., Wu, Y., Li, W., Woolfrey, J., Sinha, U., Wong, P. W., Edwards, S. T., Arfsten, A. E., Clizbe, L. A., ... Zhu, B. Y. (2009). Discovery of betrixaban (PRT054021), a highly potent, selective, and orally efficacious factor Xa inhibitor. *Bioorganic & Medicinal Chemistry Letters*, *19*(8), 2179–2185. https://doi.org/10.1016/j.bmcl.2009.02.111
30. von Itzstein, M., Wu, W. Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., Colman, P. M., Varghese, J. N., Ryan, D. M., Woods, J. M., Bethell, R. C., Hotham, V. J., Cameron, J. M., & Penn, C. R. (1993). Rational design of potent sialidase-based inhibitors of influenza virus replication. *Nature*, *363*(6428), 418–423. https://doi.org/10.1038/363418a0
31. Ellingson, S. R., Miao, Y., Baudry, J., & Smith, J. C. (2015). Multi-conformer ensemble docking to difficult protein targets. *The Journal of Physical Chemistry B*, *119*(3), 1026–1034. https://doi.org/10.1021/jp506511p
32. Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021). Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. *European Journal of Medicinal Chemistry*, *224*, Article 113705. https://doi.org/10.1016/j.ejmech.2021.113705
33. Chakraborty, R., & Parvez, S. (2020). COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. *Biochemical Pharmacology*, *180*, Article 114184. https://doi.org/10.1016/j.bcp.2020.114184

34. Gurung, A. B., Ali, M. A., Lee, J., Farah, M. A., & Al-Anazi, K. M. (2021). An updated review of computer-aided drug design and its application to COVID-19. *BioMed Research International*, *2021*, Article 8853056. https://doi.org/10.1155/2021/8853056
35. Amin, S. A., & Jha, T. (2020). Fight against novel coronavirus: A perspective of medicinal chemists. *European Journal of Medicinal Chemistry*, *201*, Article 112559. https://doi.org/10.1016/j.ejmech.2020.112559
36. [Author not listed]. (2021). A systematic review of RdRp of SARS-CoV-2 through artificial intelligence and machine learning utilizing structure-based drug design strategy. *Turkish Journal of Chemistry*, 1–30. https://doi.org/10.3906/kim-2109-30
37. Peele, K. A., Potla Durthi, C., Srihansa, T., Krupanidhi, S., Ayyagari, V. S., Babu, D. J., Indira, M., Reddy, A. R., & Venkateswarulu, T. C. (2020). Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. *Informatics in Medicine Unlocked*, *19*, Article 100345. https://doi.org/10.1016/j.imu.2020.100345
38. Serafim, M. S. M., Gertrudes, J. C., Costa, D. M. A., Oliveira, P. R., Maltarollo, V. G., & Honorio, K. M. (2021). Knowing and combating the enemy: A brief review of SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. *Bioscience Reports*, *41*(3), Article BSR20202616. https://doi.org/10.1042/BSR20202616
39. Meng, X. Y., Zhang, H. X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. *Current Computer-Aided Drug Design*, *7*(2), 146–157. https://doi.org/10.2174/157340911795677602
40. Prieto-Martínez, F. D., Arciniega, M., & Medina-Franco, J. L. (2018). Molecular docking: Current advances and challenges. *TIP Revista Especializada en Ciencias Químico-Biológicas*, *21*(Suppl. 1), 1–23. https://doi.org/10.22201/fesz.23958723e.2018.0.143
41. Lopes, P. E. M., Guvench, O., & MacKerell, A. D., Jr. (2015). Current status of protein force fields for molecular dynamics simulations. *Methods in Molecular Biology*, *1215*, 47–71. https://doi.org/10.1007/978-1-4939-1465-4_3
42. Hamzeh-Mivehroud, M., Sokouti, B., & Dastmalchi, S. (2016). The comparison of docking search algorithms and scoring functions: An overview and case studies. In S. Dastmalchi, M. Hamzeh-Mivehroud, & B. Sokouti (Eds.), *Methods and Algorithms for Molecular Docking-Based Drug Design and Discovery* (pp. 99–127). IGI Global. https://doi.org/10.4018/978-1-5225-0115-2
43. Wong, C. F. (2015). Flexible receptor docking for drug discovery. *Expert Opinion on Drug Discovery*, *10*(11), 1189–1200. https://doi.org/10.1517/17460441.2015.1078308
44. Pagadala, N. S., Syed, K., & Tuszynski, J. (2017). Software for molecular docking: A review. *Biophysical Reviews*, *9*(2), 91–102. https://doi.org/10.1007/s12551-016-0247-1
45. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of Computational Chemistry*, *30*(16), 2785–2791. https://doi.org/10.1002/jcc.21256
46. Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.

Journal of Computational Chemistry, *31*(2), 455–461. https://doi.org/10.1002/jcc.21334

47. Allen, W. J., Balius, T. E., Mukherjee, S., Brozell, S. R., Moustakas, D. T., Lang, P. T., Case, D. A., Kuntz, I. D., & Rizzo, R. C. (2015). DOCK 6: Impact of new features and current docking performance. *Journal of Computational Chemistry*, *36*(15), 1132–1156. https://doi.org/10.1002/jcc.23905
48. Unzue, A., Xu, M., Dong, J., Wiedmer, L., Spiliotopoulos, D., Caflisch, A., & Nevado, C. (2016). Fragment-based design of selective nanomolar ligands of the CREBBP bromodomain. *Journal of Medicinal Chemistry*, *59*(4), 1350–1356. https://doi.org/10.1021/acs.jmedchem.5b00172
49. Rarey, M., Kramer, B., Lengauer, T., & Klebe, G. (1996). A fast, flexible docking method using an incremental construction algorithm. *Journal of Molecular Biology*, *261*(3), 470–489. https://doi.org/10.1006/jmbi.1996.0477
50. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *Journal of Medicinal Chemistry*, *47*(7), 1739–1749. https://doi.org/10.1021/jm0306430
51. Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003). Improved protein-ligand docking using GOLD. *Proteins: Structure, Function, and Bioinformatics*, *52*(4), 609–623. https://doi.org/10.1002/prot.10465
52. Korb, O., Stützle, T., & Exner, T. E. (2009). Empirical scoring functions for advanced protein-ligand docking with PLANTS. *Journal of Chemical Information and Modeling*, *49*(1), 84–96. https://doi.org/10.1021/ci800298z
53. Abagyan, R., Totrov, M., & Kuznetsov, D. (1994). ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. *Journal of Computational Chemistry*, *15*(5), 488–506. https://doi.org/10.1002/jcc.540150503
54. Vilar, S., Cozza, G., & Moro, S. (2008). Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery. *Current Topics in Medicinal Chemistry*, *8*(18), 1555–1572. https://doi.org/10.2174/156802608786786624
55. Spitzer, R., & Jain, A. N. (2012). Surflex-Dock: Docking benchmarks and real-world application. *Journal of Computer-Aided Molecular Design*, *26*(6), 687–699. https://doi.org/10.1007/s10822-011-9533-y
56. Rao, S. N., Head, M. S., Kulkarni, A., & LaLonde, J. M. (2007). Validation studies of the site-directed docking program LibDock. *Journal of Chemical Information and Modeling*, *47*(6), 2159–2171. https://doi.org/10.1021/ci6004299
57. Wu, G., Robertson, D. H., Brooks, C. L., III, & Vieth, M. (2003). Detailed analysis of grid-based molecular docking: A case study of CDOCKER—A CHARMm-based MD docking algorithm. *Journal of Computational Chemistry*, *24*(13), 1549–1562. https://doi.org/10.1002/jcc.10306
58. Forli, S., Huey, R., Pique, M. E., Sanner, M. F., Goodsell, D. S., & Olson, A. J. (2016). Computational protein–ligand docking and virtual drug screening with the AutoDock suite. *Nature Protocols*, *11*(5), 905–919. https://doi.org/10.1038/nprot.2016.051

59. Bitencourt-Ferreira, G., & de Azevedo, W. F., Jr. (2019). Molegro virtual docker for docking. *Methods in Molecular Biology*, *2053*, 149–167. https://doi.org/10.1007/978-1-4939-9752-7_10
60. McGann, M. (2012). FRED and HYBRID docking performances on standardised datasets. *Journal of Computer-Aided Molecular Design*, *26*(8), 897–906. https://doi.org/10.1007/s10822-012-9584-8
61. Dong, D., Xu, Z., Zhong, W., & Peng, S. (2018). Parallelisation of molecular docking: A review. *Current Topics in Medicinal Chemistry*, *18*(12), 1015–1028. https://doi.org/10.2174/1568026618666180821145215
62. Maia, E. H. B., Medaglia, L. R., da Silva, A. M., & Taranto, A. G. (2020). Molecular architect: A user-friendly workflow for virtual screening. *ACS Omega*, *5*(12), 6628–6640. https://doi.org/10.1021/acsomega.9b04403
63. Gupta, M., Sharma, R., & Kumar, A. (2018). Docking techniques in pharmacology: How much promising? *Computational Biology and Chemistry*, *76*, 210–217. https://doi.org/10.1016/j.compbiolchem.2018.06.005
64. Ramírez, D., & Caballero, J. (2018). Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? *Molecules*, *23*(5), 1038. https://doi.org/10.3390/molecules23051038
65. Muhammed, M. T., & Aki-Yalcin, E. (2019). Homology modeling in drug discovery: Overview, current applications, and future perspectives. *Chemical Biology & Drug Design*, *93*(1), 12–20. https://doi.org/10.1111/cbdd.13388
66. Chi, P. B., & Liberles, D. A. (2016). Selection on protein structure, interaction, and sequence. *Protein Science*, *25*(7), 1168–1178. https://doi.org/10.1002/pro.2886
67. Muhammed, M. T., Son, Ç. D., & İzgü, F. (2019). Three dimensional structure prediction of panomycocin, a novel exo-β-1,3-glucanase isolated from *Wickerhamomyces anomalus* NCYC 434 and the computational site-directed mutagenesis studies to enhance its thermal stability for therapeutic applications. *Computational Biology and Chemistry*, *80*, 270–277. https://doi.org/10.1016/j.compbiolchem.2019.04.006
68. Lohning, A. E., Levonis, S. M., Williams-Noonan, B., & Schweiker, S. S. (2017). A practical guide to molecular docking and homology modelling for medicinal chemists. *Current Topics in Medicinal Chemistry*, *17*(18), 2023–2040. https://doi.org/10.2174/1568026617666170130110827
69. Warren, G. L., Do, T. D., Kelley, B. P., Nicholls, A., & Warren, S. D. (2012). Essential considerations for using protein–ligand structures in drug discovery. *Drug Discovery Today*, *17*(23–24), 1270–1281. https://doi.org/10.1016/j.drudis.2012.06.011
70. Voruganti, H. K., & Dasgupta, B. (2018). A novel volumetric criterion for optimal shape matching of surfaces for protein-protein docking. *Journal of Computational Design and Engineering*, *5*(2), 180–190. https://doi.org/10.1016/j.jcde.2017.10.003
71. Feher, M., & Williams, C. I. (2012). Numerical errors and chaotic behavior in docking simulations. *Journal of Chemical Information and Modeling*, *52*(3), 724–738. https://doi.org/10.1021/ci200598m
72. Cousins, K. R. (2011). Computer review of ChemDraw Ultra 12.0. *Journal of the American Chemical Society*, *133*(21), 8388. https://doi.org/10.1021/ja204075s

73. Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2019). PubChem 2019 update: Improved access to chemical data. *Nucleic Acids Research*, *47*(D1), D1102–D1109. https://doi.org/10.1093/nar/gky1033
74. Sterling, T., & Irwin, J. J. (2015). ZINC 15 – Ligand discovery for everyone. *Journal of Chemical Information and Modeling*, *55*(11), 2324–2337. https://doi.org/10.1021/acs.jcim.5b00559
75. Andricopulo, A., Guido, R., & Oliva, G. (2008). Virtual screening and its integration with modern drug design technologies. *Current Medicinal Chemistry*, *15*(1), 37–46. https://doi.org/10.2174/092986708783330683
76. Feinstein, W. P., & Brylinski, M. (2015). Calculating an optimal box size for ligand docking and virtual screening against experimental and predicted binding pockets. *Journal of Cheminformatics*, *7*(1), 18. https://doi.org/10.1186/s13321-015-0067-5
77. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. *Nature Reviews Drug Discovery*, *3*(11), 935–949. https://doi.org/10.1038/nrd1549
78. Cournia, Z., Allen, B., & Sherman, W. (2017). Relative binding free energy calculations in drug discovery: Recent advances and practical considerations. *Journal of Chemical Information and Modeling*, *57*(12), 2911–2937. https://doi.org/10.1021/acs.jcim.7b00564
79. Luzhkov, V. B. (2017). Molecular modelling and free-energy calculations of protein–ligand binding. *Russian Chemical Reviews*, *86*(3), 211–230. https://doi.org/10.1070/RCR4610
80. Kroemer, R. T. (2007). Structure-based drug design: Docking and scoring. *Current Protein & Peptide Science*, *8*(4), 312–328.
81. Coupez, B., & Lewis, R. A. (2006). Docking and scoring – Theoretically easy, practically impossible? *Current Medicinal Chemistry*, *13*(25), 2995–3003.
82. Klepeis, J. L., Lindorff-Larsen, K., Dror, R. O., & Shaw, D. E. (2009). Long-timescale molecular dynamics simulations of protein structure and function. *Current Opinion in Structural Biology*, *19*(2), 120–127. https://doi.org/10.1016/j.sbi.2009.03.004
83. Torres, P. H. M., Sodero, A. C. R., Jofily, P., & Silva-Jr, F. P. (2019). Key topics in molecular docking for drug design. *International Journal of Molecular Sciences*, *20*(18), 4574. https://doi.org/10.3390/ijms20184574
84. Lionta, E., Spyrou, G., Vassilatis, D., & Cournia, Z. (2014). Structure-based virtual screening for drug discovery: Principles, applications and recent advances. *Current Topics in Medicinal Chemistry*, *14*(16), 1923–1938. https://doi.org/10.2174/1568026614666140929124445
85. Fan, J., Fu, A., & Zhang, L. (2019). Progress in molecular docking. *Quantitative Biology*, *7*(2), 83–89. https://doi.org/10.1007/s40484-019-0172-y
86. Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., & Martinez, A. (2020). COVID-19: Drug targets and potential treatments. *Journal of Medicinal Chemistry*, *63*(21), 12359–12386. https://doi.org/10.1021/acs.jmedchem.0c00606
87. Saxena, A. (2020). Drug targets for COVID-19 therapeutics: Ongoing global efforts. *Journal of Biosciences*, *45*(1), 87. https://doi.org/10.1007/s12038-020-00067-w

88. Vardhan, S., & Sahoo, S. K. (2020). In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. *Computers in Biology and Medicine*, *124*, Article 103936. https://doi.org/10.1016/j.compbiomed.2020.103936
89. Rubio-Martínez, J., Jiménez-Alesanco, A., Ceballos-Laita, L., Ortega-Alarcón, D., Vega, S., Calvo, C., Benítez, C., Abian, O., Velázquez-Campoy, A., ... Pérez, J. J. (2021). Discovery of diverse natural products as inhibitors of SARS-CoV-2 Mpro protease through virtual screening. *Journal of Chemical Information and Modeling*, *61*(12), 6094–6106. https://doi.org/10.1021/acs.jcim.1c00951
90. Sharma, P., Vijayan, V., Pant, P., Sharma, M., Vikram, N., Kaur, P., Singh, T. P., & Sharma, S. (2020). Identification of potential drug candidates to combat COVID-19: A structural study using the main protease (Mpro) of SARS-CoV-2. *Journal of Biomolecular Structure and Dynamics*, 1–11. https://doi.org/10.1080/07391102.2020.1798286
91. Gorgulla, C., Padmanabha Das, K. M., Leigh, K. E., Cespugli, M., Fischer, P. D., Wang, Z. F., ... Arthanari, H. (2021). A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. *iScience*, *24*(2), Article 102021. https://doi.org/10.1016/j.isci.2020.102021
92. Ton, A. T., Gentile, F., Hsing, M., Ban, F., & Cherkasov, A. (2020). Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. *Molecular Informatics*, *39*(8), 2000028. https://doi.org/10.1002/minf.202000028
93. Rossetti, G. G., Ossorio, M. A., Rempel, S., Kratzel, A., Dionellis, V. S., Barriot, S., Tropia, L., Gorgulla, C., Arthanari, H., Thiel, V., Mohr, P., Gamboni, R., & Halazonetis, T. D. (2022). Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits. *Scientific Reports*, *12*(1), Article 2505. https://doi.org/10.1038/s41598-022-06306-4
94. Huang, H., Zhang, G., Zhou, Y., Lin, C., Chen, S., Lin, Y., Mai, S., & Huang, Z. (2018). Reverse screening methods to search for the protein targets of chemopreventive compounds. *Frontiers in Chemistry*, *6*, 138. https://doi.org/10.3389/fchem.2018.00138
95. Xu, X., Huang, M., & Zou, X. (2018). Docking-based inverse virtual screening: Methods, applications, and challenges. *Biophysics Reports*, *4*(1), 1–16. https://doi.org/10.1007/s41048-017-0045-8
96. Gao, Z., Li, H., Zhang, H., Liu, X., Kang, L., Luo, X., Zhu, W., Chen, K., Wang, X., & Jiang, H. (2008). PDTD: A web-accessible protein database for drug target identification. *BMC Bioinformatics*, *9*(1), 104. https://doi.org/10.1186/1471-2105-9-104
97. Chen, X., Ji, Z. L., & Chen, Y. Z. (2002). TTD: Therapeutic target database. *Nucleic Acids Research*, *30*(1), 412–415. https://doi.org/10.1093/nar/30.1.412
98. Li, H., Gao, Z., Kang, L., Zhang, H., Yang, K., Yul, K., Luo, X., Zhu, W., Chen, K., & Shen, J. (2006). TarFisDock: A web server for identifying drug targets with docking approach. *Nucleic Acids Research*, *34*(Web Server issue), W219–W224. https://doi.org/10.1093/nar/gkl114
99. Wang, J. C., Chu, P. Y., Chen, C. M., & Lin, J. H. (2012). idTarget: A web server for identifying protein targets of small chemical molecules with robust scoring functions

and a divide-and-conquer docking approach. *Nucleic Acids Research*, *40*(W1), W393–W399. https://doi.org/10.1093/nar/gks496

100. Chen, Y. Z., & Zhi, D. G. (2001). Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. *Proteins: Structure, Function, and Bioinformatics*, *43*(2), 217–226. https://doi.org/10.1002/1097-0134(20010501)43:2<217::AID-PROT1032>3.0.CO;2-G

101. Bullock, C., Cornia, N., Jacob, R., Remm, A., Peavey, T., Weekes, K., Mallory, C., Oxford, J. T., McDougal, O. M., & Andersen, T. L. (2013). DockoMatic 2.0: High throughput inverse virtual screening and homology modeling. *Journal of Chemical Information and Modeling*, *53*(8), 2161–2170. https://doi.org/10.1021/ci400047w

102. Yang, L., Luo, H., Chen, J., Xing, Q., & He, L. (2009). SePreSA: A server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome. *Nucleic Acids Research*, *37*(Suppl. 2), W406–W412. https://doi.org/10.1093/nar/gkp312

103. Zhao, J., Yang, P., Li, F., Tao, L., Ding, H., Rui, Y., Cao, Z., & Zhang, W. (2012). Therapeutic effects of astragaloside IV on myocardial injuries: Multi-target identification and network analysis. *PLoS One*, *7*(9), e44938. https://doi.org/10.1371/journal.pone.0044938

104. Klein, E., & Bourdette, D. (2013). Postmarketing adverse drug reactions: A duty to report? *Neurology: Clinical Practice*, *3*(4), 288–294. https://doi.org/10.1212/CPJ.0b013e3182a1b9f0

105. Yoo, S., Noh, K., Shin, M., Park, J., Lee, K. H., Nam, H., & Lee, D. (2018). In silico profiling of systemic effects of drugs to predict unexpected interactions. *Scientific Reports*, *8*(1), Article 1612. https://doi.org/10.1038/s41598-018-19614-5

106. Fan, S., Geng, Q., Pan, Z., Li, X., Tie, L., Pan, Y., & Li, X. (2012). Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. *BMC Systems Biology*, *6*(1), 152. https://doi.org/10.1186/1752-0509-6-152

107. Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016). The SIDER database of drugs and side effects. *Nucleic Acids Research*, *44*(D1), D1075–D1079. https://doi.org/10.1093/nar/gkv1075

108. Luo, H., Fokoue-Nkoutche, A., Singh, N., Yang, L., Hu, J., & Zhang, P. (2018). Molecular docking for prediction and interpretation of adverse drug reactions. *Combinatorial Chemistry & High Throughput Screening*, *21*(5), 314–322. https://doi.org/10.2174/1386207321666180524110013

109. Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018). A perspective on multi-target drug discovery and design for complex diseases. *Clinical and Translational Medicine*, *7*(1), 3. https://doi.org/10.1186/s40169-017-0181-2

110. Anighoro, A., Bajorath, J., & Rastelli, G. (2014). Polypharmacology: Challenges and opportunities in drug discovery. *Journal of Medicinal Chemistry*, *57*(19), 7874–7887. https://doi.org/10.1021/jm5006463

111. Wei, D., Jiang, X., Zhou, L., Chen, J., Chen, Z., He, C., Yang, K., Liu, Y., Pei, J., & Lai, L. (2008). Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. *Journal of Medicinal Chemistry*, *51*(24), 7882–7888. https://doi.org/10.1021/jm8010096

112. Zhang, W., Pei, J., Lai, L. (2017). Computational multitarget drug design. *Journal of Chemical Information and Modeling*, *57*(3), 403–412. https://doi.org/10.1021/acs.jcim.6b00491

113. Gasymov, O. K., Celik, S., Agaeva, G., Akyuz, S., Kecel-Gunduz, S., Qocayev, N. M., Ozel, A. E., Agaeva, U., Bakhishova, M., & Aliyev, J. A. (2021). Evaluation of anti-cancer and anti-covid-19 properties of cationic pentapeptide Glu-Gln-Arg-Pro-Arg, from rice bran protein and its d-isomer analogs through molecular docking simulations. *Journal of Molecular Graphics and Modelling*, *108*, Article 107999. https://doi.org/10.1016/j.jmgm.2021.107999

114. Anighoro, A., Pinzi, L., Marverti, G., Bajorath, J., & Rastelli, G. (2017). Heat shock protein 90 and serine/threonine kinase B-Raf inhibitors have overlapping chemical space. *RSC Advances*, *7*(49), 31069–31074. https://doi.org/10.1039/C7RA05889F

115. Chopra, G., & Samudrala, R. (2016). Exploring polypharmacology in drug discovery and repurposing using the CANDO platform. *Current Pharmaceutical Design*, *22*(21), 3109–3123. https://doi.org/10.2174/1381612822666160325121943

116. Luo, H., Chen, J., Shi, L., Mikailov, M., Zhu, H., Wang, K., He, L., & Yang, L. (2011). DRAR-CPI: A server for identifying drug repositioning potential and adverse drug reactions via the chemical–protein interactome. *Nucleic Acids Research*, *39*(Suppl. 2), W492–W498. https://doi.org/10.1093/nar/gkr299

117. Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., Whaley, R., Glennon, R. A., Hert, J., Thomas, K. L. H., Edwards, D. D., Shoichet, B. K., & Roth, B. L. (2009). Predicting new molecular targets for known drugs. *Nature*, *462*(7270), 175–181. https://doi.org/10.1038/nature08506

118. March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H., & Rastelli, G. (2017). On the integration of in silico drug design methods for drug repurposing. *Frontiers in Pharmacology*, *8*, 298. https://doi.org/10.3389/fphar.2017.00298

119. Kumar, S., & Kumar, S. (2019). *Molecular docking: A structure-based approach for drug repurposing*. Elsevier. https://doi.org/10.1016/B978-0-12-816125-8.00006-7

120. Dotolo, S., Marabotti, A., Facchiano, A., & Tagliaferri, R. (2021). A review on drug repurposing applicable to COVID-19. *Briefings in Bioinformatics*, *22*(2), 726–741. https://doi.org/10.1093/bib/bbaa288

121. Elmezayen, A. D., Al-Obaidi, A., Şahin, A. T., & Yelekçi, K. (2020). Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. *Journal of Biomolecular Structure and Dynamics*, *39*(8), 2980–2992. https://doi.org/10.1080/07391102.2020.1758791

122. Ibrahim, M. A. A., Abdelrahman, A. H. M., & Hegazy, M. E. F. (2020). In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. *Journal of Biomolecular Structure and Dynamics*, *39*(15), 5737–5748. https://doi.org/10.1080/07391102.2020.1791958